Public release date: 21-Jun-2013 [ | E-mail | Share ] Contact: Cara Lasala cara.lasala@cshs.org 310-423-7798 Cedars-Sinai Medical Center LOS ANGELES (June 21, 2013) Corneal blindness affects roughly 8 million people worldwide, and traditional treatments and surgical interventions have seen little long-term success. With a new vision for stem cell corneal transplantation, and a $1.25 million grant from the National Eye Institute, Cedars-Sinai co-investigators Alexander V. Ljubimov, PhD, FARVO, and Clive Svendsen, PhD, hope to treat previously untreatable patients suffering with corneal blindness. "Our proposed and first-of-a-kind research deals with collecting human eye cells, reprograming them back in time to a stem cell state and then using them to create a corneal cell source for transplantation. If successful, this could result in future human clinical trials that may lead to improved vision and overall quality of life," said Ljubimov, principal investigator of the grant and director of the Eye Program at the Cedars-Sinai Regenerative Medicine Institute. "We are first experimenting with allogeneic cells from eye donors, but hope to use person's own cells in the near future." A common cause of corneal blindness is limbal epithelial stem cell deficiency, which means that a patient's history of genetics or eye injuries results … Continue reading →

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ --Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013. IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind". IG-001 (Cynviloq) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL … Continue reading →

A new standard in pluripotent stem cell characterization -- TaqMan hPSC Scorecard trade; Panel See it now at http://www.lifetechnologies.com/scorecard For Research Use Only. Not for use in diagnostic procedures. A new standard in pluripotent stem cell ... By: LifeTechnologiesCorp … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/p7rrs9/autologous_stem) has announced the addition of the "Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases)" report to their offering. This research report titled Autologous Cell Therapy (2012-2017) provides details about various ACT based treatments and their application areas. Every health regulatory bodies will be expecting companies and universities to develop therapy treatments, which are safer, affordable, robust, rapid, easy to use, effective and deliverable to the end user. ACT treatments for particular application areas it is safe, experiencing robust growth, minimal steps of procedure to follow and rapid in deriving the results. As for now the treatment prices are not affordable, but by the intrusion of government bodies, it will definitely experience immense market growth. The report gives a detailed analysis about the state of autologous cell therapies. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company, revenue forecasting. It includes the latest therapy … Continue reading →

An Australian-based biomedical company has approached sports scientists and doctors, including those at AFL clubs, spruiking contentious ''frontier'' stem cell treatment to help players recover from injury. The developmental and largely unproven treatment, banned by the World Anti-Doping Agency if it is performance-enhancing, but approved if it is solely for injury purposes, involves fat cells being taken from a player and processed. These processed stem cells are then injected into the injured tendon or joint, in the hope it stimulates cartilage growth to ease pain. But at a time when the Essendon and Melbourne football clubs are under investigation for a supplements scandal, allegedly used in part to fast-track recovery for injured players, an AFL medico and club doctors have told Fairfax Media they remain cautious about stem cell treatment. Advertisement They confirmed the company and treatment was known within AFL circles but some said there was little or no proof that it worked. There have been reports the company, Regeneus, along with other biomedical companies, are willing to provide free treatment in the hope of using that player's rights to help sell the product. This particular treatment costs $9000 and there is no Medicare rebate. There have also been … Continue reading →